Capital BioVentures launches first cohort for the ASCENT program: Fit for funding, empowering breakthrough biotech

Capital BioVentures (CBV), a leading biotech accelerator, dedicated to supporting the growth of early-stage life sciences companies, recently announced the launch of its newest offering, the ASCENT Program. Designed to accelerate the development and funding readiness of promising therapeutic start-ups, ASCENT is a virtual six-month program providing expert-led seminars, workshops, office hours, one-on-one coaching from seasoned executives, strategic investor exposure, and 360 feedback. This program is supported by the Government of Canada through funding from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Congratulations to the nine companies joining the first cohort! We are especially proud to see OBIO-affiliated companies, Atorvia Health Technologies, CEREBRO Therapeutics, Cura Therapeutics, i-RNA Corporation, and 20/20 OptimEyes Technologies, among the inaugural ASCENT cohort.